One of my studies (A) involve sequencing the microbiome. After selecting the variable region and the primers for the targeted region of the 16S sequence. The samples were sent to a platform.

For another study (B) we used the same strategy (same primers, region, machine...) but another platform. However we obtained from this platform a lot more sequences:
In study A the mean sequences per sample are 10k, while in the study B the mean sequences per sample are 80k

I consulted with others and it seems that the study A we under-sampled and in study B we over-sampled.

I can understand that by under-sampling we didn't obtain enough reads to be sure about the microbiome present in the sample. But what does it mean to over-sampling?

That expert I consulted suggested normalize the data to fewer sequences, discarding information we already have. I can understand that the sequencing has errors and can create chimeras but the resulting consensus sequences of the OTUs have found a match with databases of microorganisms. What or how should I take into account that I over-sampled?


As you sequence a library you are sampling from the pool of all possible oligonucleotides found in it. This is a stochastic process, meaning that you are more likely to sequence a piece of DNA that is more prevalent.

As you increase the number of reads that you sequence for a library, you decrease the chances of seeing a new read that you have not yet seen before. If you plot the number of unique reads per total reads sequenced, it will look something like the cumulative density function of the exponential distribution, where you have diminishing returns on unique sequences as you continue to sequence.

If you sequence a library and quickly stop seeing unique reads, we say that this library has low complexity. Therefore, you have "oversampled" it if you sequence too deeply. I am guessing that your metagenomics library actually has a lot fewer species/unique sequences than they anticipated, and that you sequenced deeply anticipating more.

Edit: In response to your comments, the bigger problem in 16S analyses is not sequencing too deeply, it is over-amplifying your samples such that they no longer represent what is actually in your gut microbiome samples. In this case if you used read normalization you would not accurately represent what was in the library that you sequenced since the amplified molecules (16S) are so small that you only have len(16S molecule)-(read len) + 1 possible reads in each direction. You might consider removing PCR duplicates with GATK but this will still have the same effect of not representing what was in the sequencing pool. It is very possible that you have many PCR duplicates after 16S amplification. I generally don't trust amplicon sequencing for quantitive analyses, and don't really trust for low coverage "is-this-species-there-or-not" either, especially when dealing with the 'dark matter' of uncharacterized species. You might be well off just asking "is this species present in high coverage at this time point?"

| improve this answer | |
  • $\begingroup$ Thanks for your answer. The problem raise when the same samples in both platforms yield different results (but take into account that I am using OTUs not unique reads). I can upload an image if needed. Anyway, how to take oversampling into account (If it is something to take care of)? I am worried that I can't then compare the results between the studies $\endgroup$ – llrs Feb 22 '18 at 15:52
  • $\begingroup$ BTW, wouldn't that be considered then deep-sequencing? $\endgroup$ – llrs Feb 22 '18 at 16:01
  • $\begingroup$ Yes, this is "deep-sequencing", however I really think that term is overused and overhyped. As you can see in your case, deep sequencing actually causes its own problems with normalization on platforms like Illumina or with PCR-based libraries. :) Whether or not the sample coverage requires special handling depends on the downstream analysis that you would like to perform. Is this whole-genome shotgun metagenomics, something like 16S amplicons, or something else? $\endgroup$ – conchoecia Feb 22 '18 at 16:06
  • $\begingroup$ As described in the question it is 16S done in MiSeq. I want to perform integration with RNA-seq data and analyze them on its own via comparing different times, response, localization (it is gut sequencing), sex ... $\endgroup$ – llrs Feb 22 '18 at 16:27

I don't think there's anything inherently wrong with sequencing to high depth (though naive approaches to dealing with sequencing errors such as singleton removal may fail if the depth is so high that the same errors may be encountered repeatedly by chance). The bigger issue is that they are over sampled relative to the undersampled microbiomes. This does complicate comparisons, particularly for things like OTU richness. The obvious solution is to down-sample the oversampled microbiomes so you have the same number of reads for each. This is probably unnecessary if your analyzing the oversampled microbiomes on their own.

| improve this answer | |
  • $\begingroup$ I think like this answer specially because the tool I use to transform the fastq files to OTUs is specially designed to remove singletons and chimeras. $\endgroup$ – llrs Feb 22 '18 at 16:57

Your Answer

By clicking “Post Your Answer”, you agree to our terms of service, privacy policy and cookie policy

Not the answer you're looking for? Browse other questions tagged or ask your own question.